162 related articles for article (PubMed ID: 32068354)
1. Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing.
Cai W; Leil TA; Gibiansky L; Krishna M; Zhang H; Gu H; Sun H; Throup J; Banerjee S; Girgis I
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):689-698. PubMed ID: 32068354
[TBL] [Abstract][Full Text] [Related]
2. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
4. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
5. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
7. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
8. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
9. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
[TBL] [Abstract][Full Text] [Related]
11. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
12. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
Yan X; Ruixo JJP; Krzyzanski W
AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
[TBL] [Abstract][Full Text] [Related]
13. In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.
Reid J; Zamuner S; Edwards K; Rumley SA; Nevin K; Feeney M; Zecchin C; Fernando D; Wisniacki N
Br J Clin Pharmacol; 2018 Oct; 84(10):2280-2291. PubMed ID: 29900565
[TBL] [Abstract][Full Text] [Related]
14. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
15. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
17. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers.
Peters E; Heuberger JAAC; Tiessen R; van Elsas A; Masereeuw R; Arend J; Stevens J; Pickkers P
Clin Pharmacokinet; 2016 Oct; 55(10):1227-1237. PubMed ID: 27147514
[TBL] [Abstract][Full Text] [Related]
19. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
[TBL] [Abstract][Full Text] [Related]
20. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
Grimm HP
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]